JP2001507342A5 - - Google Patents

Download PDF

Info

Publication number
JP2001507342A5
JP2001507342A5 JP1998527715A JP52771598A JP2001507342A5 JP 2001507342 A5 JP2001507342 A5 JP 2001507342A5 JP 1998527715 A JP1998527715 A JP 1998527715A JP 52771598 A JP52771598 A JP 52771598A JP 2001507342 A5 JP2001507342 A5 JP 2001507342A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998527715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001507342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/021532 external-priority patent/WO1998026773A1/en
Publication of JP2001507342A publication Critical patent/JP2001507342A/ja
Publication of JP2001507342A5 publication Critical patent/JP2001507342A5/ja
Abandoned legal-status Critical Current

Links

JP52771598A 1996-12-17 1997-11-21 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 Abandoned JP2001507342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3275396P 1996-12-17 1996-12-17
US60/032,753 1996-12-17
PCT/US1997/021532 WO1998026773A1 (en) 1996-12-17 1997-11-21 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing

Publications (2)

Publication Number Publication Date
JP2001507342A JP2001507342A (ja) 2001-06-05
JP2001507342A5 true JP2001507342A5 (https=) 2005-07-14

Family

ID=21866631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52771598A Abandoned JP2001507342A (ja) 1996-12-17 1997-11-21 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用

Country Status (14)

Country Link
US (1) US6340709B1 (https=)
EP (1) EP0946166B1 (https=)
JP (1) JP2001507342A (https=)
AT (1) ATE259640T1 (https=)
AU (1) AU737117B2 (https=)
BR (1) BR9714142A (https=)
CA (1) CA2264692A1 (https=)
DE (1) DE69727695T2 (https=)
DK (1) DK0946166T3 (https=)
ES (1) ES2212142T3 (https=)
NZ (1) NZ334925A (https=)
PT (1) PT946166E (https=)
WO (1) WO1998026773A1 (https=)
ZA (1) ZA9711279B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123901A (en) * 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
HU222986B1 (hu) * 1995-12-22 2004-01-28 Warner-Lambert Co. A mátrix metalloproteinázok működését gátló aromás ketosavak és azok származékai
RU2208609C2 (ru) * 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
JP4074043B2 (ja) 2000-03-27 2008-04-09 株式会社資生堂 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002041886A1 (en) * 2000-11-23 2002-05-30 British Biotech Pharmaceuticals Ltd Ydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
GB0204159D0 (en) * 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20080269282A1 (en) * 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US20090136718A1 (en) * 2007-11-28 2009-05-28 Paul Dacey Reinforced Bonded Constructs
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014002459A (es) 2011-08-30 2014-04-10 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
CN106715421A (zh) 2014-07-17 2017-05-24 Chdi基金会股份有限公司 用于治疗hiv相关病症的方法和组合物
CN111249281B (zh) * 2020-03-26 2020-11-24 徐州医科大学 Trpml1特异性小分子抑制剂ml-si3的新用途
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
KR102612229B1 (ko) * 2021-05-21 2023-12-08 가천대학교 산학협력단 N-[(4'-브로모[1,1'-바이페닐]-4-일)설포닐]-l-발린 또는 이의 약제학적으로 허용 가능한 염을 포함하는 아밀로이드 베타의 올리고머화 및 피브릴화 억제용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
BR9509237A (pt) 1994-10-05 1997-10-21 Chiroscience Ltd Compostos peptidila e seu uso terapêutico como inibidores de metaloproteases
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
JPH11506097A (ja) * 1995-06-02 1999-06-02 ワーナー−ランバート・コンパニー マトリックスメタロプロテイナーゼの三環式阻害剤
IL123901A (en) * 1995-11-17 2003-06-24 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
HU222986B1 (hu) * 1995-12-22 2004-01-28 Warner-Lambert Co. A mátrix metalloproteinázok működését gátló aromás ketosavak és azok származékai
NZ332711A (en) 1996-05-17 2000-06-23 Warner Lambert Co Biphenylsulfonylamino carboxylic acid derivatives as matrix metalloproteinase inhibitors

Similar Documents

Publication Publication Date Title
JP2000511788A5 (https=)
JP2000511435A5 (https=)
JP2000506165A5 (https=)
JP2001508012A5 (https=)
JP2000514474A5 (https=)
JP2000505452A5 (https=)
JP2000505690A5 (https=)
JP2001503155A5 (https=)
JP2000513888A5 (https=)
JP2001504244A5 (https=)
JP2001509188A5 (https=)
JP2001504104A5 (https=)
JP2001504579A5 (https=)
JP2001504230A5 (https=)
JP2000511806A5 (https=)
JP2000502472A5 (https=)
JP2001502521A5 (https=)
JP2000501825A5 (https=)
JP2001505567A5 (https=)
JP2001504730A5 (https=)
JP2000508645A5 (https=)
JP2000515132A5 (https=)
JP2000513072A5 (https=)
JP2001512305A5 (https=)
JP2001523409A5 (https=)